The Science of Sequencing: Navigating Complexities in HER2+ Metastatic Breast Cancer Care Beyond Second-line Therapy

Community oncologists, neuro-oncologists, and other oncology HCPs who treat patients with HER2+ metastatic breast cancer will be able to summarize and describe the treatment sequence of HER2-targeted therapies and tyrosine kinase inhibitor combination regimens, and interpret recent clinical data, to improve patient outcomes.

Share

Program Content

Events

Activities

Sequencing Tx HER2 MBC
Expert Thoughts on Sequencing Therapy for Patients With HER2+ Metastatic Breast Cancer 
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: January 29, 2025

Expires: January 28, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.